The Relative Strength (RS) Rating for Baxter International entered a higher percentile Tuesday, as it got a lift from 62 to 71.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they launch their largest runs. See if Baxter International can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Baxter International is not currently offering a proper buying opportunity. See if the stock goes on to form a chart pattern that could launch a new move.
The company posted -11% EPS growth in its most recent report, while sales growth came in at 1%. The company is expected to report its latest performance numbers on or around Apr. 24.
The company holds the No. 32 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
